Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

Related Experiment Video

Updated: Jul 14, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Anna Rodina1, Maria Vilenchik, Kamalika Moulick

  • 1Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA.

Nature Chemical Biology
|July 3, 2007
PubMed

Insights

Heat shock protein 90 (Hsp90) uniquely regulates apoptosis in small-cell lung carcinoma, acting as a specific antiapoptotic factor. This discovery highlights Hsp90

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Heat shock protein 90 (Hsp90) is crucial for malignant transformation by stabilizing oncoproteins.
  • The specific role of Hsp90 in regulating the antiapoptotic phenotype during transformation is not well understood.
  • Small-cell lung carcinoma (SCLC) presents a unique cellular model for studying apoptosis regulation.

Purpose of the Study:

  • To investigate the transformation-specific regulation of the antiapoptotic phenotype by Hsp90.
  • To determine if Hsp90 acts as a general inhibitor of apoptosis or has a specialized role.
  • To elucidate the mechanism by which Hsp90 regulates apoptosis in SCLC.

Main Methods:

  • Utilized selective chemical compounds to investigate Hsp90 function.
  • Studied apoptosis regulation in small-cell lung carcinoma cell systems.
  • Differentiated Hsp90's role from the well-characterized antiapoptotic chaperone Hsp70.

Main Results:

  • Small-cell lung carcinoma is a unique system where apoptosis is primarily regulated by Hsp90.
  • Hsp90 functions as a specific inhibitor of apoptosis in SCLC, not a general one.
  • Apoptosis in SCLC is dependent on the intrinsic pathway, without upstream caspase involvement or non-apoptosome pathways.

Conclusions:

  • Hsp90 plays a critical, transformation-specific role in regulating apoptosis in malignant cells.
  • The findings reveal a unique interplay between chaperones in controlling apoptosis in SCLC.
  • This study provides evidence for Hsp90 as a key regulator in the intrinsic apoptotic pathway in SCLC.

More Related Videos

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...